MAPT and Alzheimer disease: In addition, glycosaminoglycans (GAGs), including the heparan sulfate of HSPG, have altered the ability to bind FGF and tau in AD patients77, suggesting that the HSPG–FGFR3 heterocomplex may synergistically interact with tau in the presence of Aβ.